Mice with the Alzheimer's disease-associated APOE4 and the APOE2 genes were more likely to die from COVID-19 than those with the APOE3 gene. Those with APOE4 and APOE2 genes had more virus replication in the lungs, higher inflammation, and increased tissue damage following coronavirus infection.
Microglia that express the Alzheimer's associated APOE4 genetic variant are unable to effectively metabolize lipids. This causes lipids to build up, promoting inflammation and preventing effective neurotransmission.
In cognitively healthy people with a genetic risk for Alzheimer's, retinal changes have been associated with alterations in the entorhinal cortex, hippocampus, and lingual gyrus. Researchers say retinal changes can be used to track changes in brain structures associated with Alzheimer's in those with genetic risk factors.
People with higher levels of omega-3 DHA in their blood are 49% less likely to develop dementia than those with lower levels. Researchers say adding additional omega-3 DHA to the diet, especially in those with the Alzheimer's associated Apoe4 gene, could slow the development and progress of dementia.
A new study outlines and defines sex differences in outcomes of tailored Alzheimer's disease clinical interventions.
15 newly discovered "hotspots" in the genome that either speed up or slow down brain aging could be new targets for the development of Alzheimer's medications and therapies for other brain disorders.
Carriers of the Alzheimer's associated APOE4 gene have more than double the risk of developing severe COVID-19, a new study reports. Additionally, more microscopic hemorrhages were found in the brains of APOE4 carriers who contracted coronavirus. Researchers report those with the APOE4 gene also are more susceptible to developing long-term symptoms following COVID infection, including an increased risk of mental fatigue.
A new framework reveals Alzheimer's disease is far more complex than previously believed. Rather than being a disease where the same causes produce the same outcomes, researchers found three different models for the disease, each with its own characterizations and dynamics.
Dasatinib, an FDA-approved drug for chronic myeloid leukemia, and an experimental drug for liver cancer reduced neuroinflammation, tau phosphorylation, and amyloid secretion in cell cultures of post-mortem brain samples of those with the APOE4 Alzheimer's associated gene.
Inhibiting the NHE6 gene abolished the formation of amyloid-beta plaques in mouse models of Alzheimer's disease.